Cindy Cullen – Automated Bedside Glucose Monitoring for Critical Care

Posted October 18, 2017

OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU

OptiScan Biomedical’s OptiScanner® 5000 Receives 510(k) Clearance from US Food and Drug Administration for the First Inline Continuous Glucose Monitor in the SICU First-of-its-Kind Automated, [...]

By Cindy Cullen

In Press Releases

Posted April 28, 2014

OptiScan Biomedical Enrolls First Patient in Pivotal U.S. Clinical Study of OptiScanner® 5000

Pivotal Trial to Build on Previous Positive Studies; Aims to Further Demonstrate Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System in the ICU — HAYWARD, Calif., [...]

By Cindy Cullen

In Press Releases

Posted March 21, 2013

33rd Annual ISICEM Conference Symposium Features Breakthrough Clinical Results Supporting OptiScanner™ from OptiScan Biomedical

Industry Thought-Leaders Highlight Paradigm-Shifting Potential of Automated, Bedside Glucose Monitoring System for Critically Ill Patients BRUSSELS, Belgium, March 21, 2013 – OptiScan [...]

By Cindy Cullen

In Press Releases

Posted March 21, 2012

OptiScan Biomedical Presents Study Results Demonstrating OptiScanner’s Excellent Glucose Monitoring Accuracy in Critically Ill ICU Patients

All Measurement Readings Demonstrate Sufficient Accuracy to Guide Clinical Treatment Decisions; Results Achieved in Most Severely Ill Patients — BRUSSELS, March 21, 2012 – OptiScan [...]